Home Cart Sign in  
Chemical Structure| 130693-82-2 Chemical Structure| 130693-82-2

Structure of Dorzolamide HCl
CAS No.: 130693-82-2

Chemical Structure| 130693-82-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dorzolomide HCl is a potent and water-soluble inhibitor of human carbonic anhydrase II and IV with Ki of 1.9 nM and 31 nM respectively and used as anti-glaucoma agent.

Synonyms: MK-507; L-671,152; (4Strans)4(ethylamino)56dihydro6methyl4Hthieno23bthiopyran2sulfonamide 77dioxide monohydrochloride.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dorzolamide HCl

CAS No. :130693-82-2
Formula : C10H17ClN2O4S3
M.W : 360.90
SMILES Code : O=S(C(S1)=CC([C@@H](NCC)C[C@@H]2C)=C1S2(=O)=O)(N)=O.[H]Cl
Synonyms :
MK-507; L-671,152; (4Strans)4(ethylamino)56dihydro6methyl4Hthieno23bthiopyran2sulfonamide 77dioxide monohydrochloride.
MDL No. :MFCD00884659
InChI Key :OSRUSFPMRGDLAG-QMGYSKNISA-N
Pubchem ID :6918132

Safety of Dorzolamide HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312+P330-P501

Isoform Comparison

Biological Activity

Target
  • Carbonic Anhydrase IV

    Carbonic anhydrase IV, Ki:31 nM

  • Carbonic Anhydrase I

    Carbonic anhydrase I, Ki:6000 nM

  • Carbonic Anhydrase II

    Carbonic anhydrase II, Ki:1.9 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
CH22 cells 50 µM 48 hours Inhibited chordoma cell proliferation and migration PMC8485454
U-CH1 cells 50 µM 48 hours Inhibited chordoma cell proliferation and migration PMC8485454
Bone marrow monocytes (BMMs) 3.125 µM to 200 µM 7 days Inhibited osteoclast differentiation PMC8485454

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Chordoma xenograft model Intraperitoneal injection 30 mg/kg Once daily for 2 weeks Inhibited chordoma formation PMC8485454
DBA/2J mice Glaucoma model Topical application 2% Single dose, observed at 1 and 2 hours post-administration To test the hypothesis that acute topical dorzolamide decreases intraocular pressure (IOP) and increases retinal and choroidal blood flow in the DBA/2J Mice model of glaucoma. Results showed that dorzolamide significantly lowered IOP and increased retinal and choroidal blood flow in older DBA/2J mice. PMC4777278
DBA/2J mice Glaucoma model Topical application 2% Single dose, effects measured at 1 and 2 hours post-application To test the hypothesis that acute topical dorzolamide decreases intraocular pressure and increases retinal and choroidal blood flow in the DBA/2J Mice model of glaucoma. Results showed that dorzolamide lowered IOP and increased retinal and choroidal blood flow in older DBA/2J mice. PMC4777278
New Zealand albino rabbits Anesthetized rabbit model Topical application 2%, 50 μL Single dose, observed for 120 minutes To determine the effects of dorzolamide on choroidal and ciliary blood flow and aqueous production. Results showed that dorzolamide lowered IOP by 19% and aqueous flow by 17%, increased ciliary blood flow by 18%, but had no significant effect on choroidal blood flow. PMC4572513
Long-Evans rats Diabetes model Intravenous injection 15 mg/kg Single injection To investigate the effect of Dorzolamide on retinal pH regulation in diabetic rats. Results showed that Dorzolamide dramatically increased retinal acidity in both control and diabetic retinas to a similar degree, but in diabetics, the effect tended to increase with time and after 2 hours could be two to three times larger than at the beginning. PMC6383832

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.85mL

2.77mL

1.39mL

27.71mL

5.54mL

2.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories